NORTHWEST BIOTHERAPEUTICS INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
NORTHWEST BIOTHERAPEUTICS INC (NWBO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $741.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-16.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2020-03-16
- NORTHWEST BIOTHERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2019-12-31 was $414.00K.
- NORTHWEST BIOTHERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- NORTHWEST BIOTHERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-09-30 was $800.00K, a 100.00% increase year-over-year.
- NORTHWEST BIOTHERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-06-30 was $14.50M.
- NORTHWEST BIOTHERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2019 was $741.00K, a 95.45% decline from fiscal 2018.
- NORTHWEST BIOTHERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2018 was $16.30M, a 1937.50% increase from fiscal 2017.
- NORTHWEST BIOTHERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2017 was $800.00K, a 94.12% decline from fiscal 2016.
- NORTHWEST BIOTHERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2016 was $13.60M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2019-12-31 | $414.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $741.00K 10-K · filed 2020-03-16 | ||
| 2019-09-30 | $327.00K 10-Q · filed 2019-11-12 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-02 | $800.00K derived: sum of 2 quarters · filed 2019-04-02 | $15.30M derived: sum of 3 quarters · filed 2019-04-02 | $16.30M 10-K · filed 2019-04-02 |
| 2018-09-30 | $800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-16 | $15.30M derived: sum of 2 quarters · filed 2018-11-16 | $16.30M 10-Q · filed 2018-11-16 | $16.60M derived: sum of 4 quarters · filed 2018-11-16 |
| 2018-06-30 | $14.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $15.50M 10-Q · filed 2018-08-14 | $15.80M derived: sum of 3 quarters · filed 2018-08-14 | $16.20M derived: sum of 4 quarters · filed 2018-08-14 |
| 2018-03-31 | $1.00M 10-Q · filed 2018-05-16 | $1.30M derived: sum of 2 quarters · filed 2018-05-16 | $1.70M derived: sum of 3 quarters · filed 2018-05-16 | |
| 2017-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-17 | $700.00K derived: sum of 2 quarters · filed 2018-04-17 | $800.00K 10-K · filed 2018-04-17 | |
| 2017-09-30 | $400.00K 10-Q · filed 2017-11-20 | $500.00K 10-Q · filed 2017-11-20 | ||
| 2017-06-30 | $700.00K 10-Q · filed 2017-08-21 | |||
| 2016-12-31 | $13.60M 10-K · filed 2018-04-17 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-04-01 | $1.40M 10-K · filed 2014-04-01 | ||
| 2013-09-30 | $1.40M 10-Q · filed 2013-11-15 | |||
| 2012-12-31 | -$2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2014-04-01 | $100.00K 10-K · filed 2014-04-01 | ||
| 2012-09-30 | $2.60M 10-Q · filed 2013-11-15 |